Anoro Ellipta

(trade name)


Therapeutic: bronchodilators
Pharmacologic: anticholinergics
Pregnancy Category: C


Maintenance management of airflow obstruction in patients with COPD.


Umeclidinium— acts as an anticholinergic by inhibiting M3 muscarinic receptors in bronchial smooth muscle resulting in bronchodilation; vilanterol— a beta2-adrergic agonist stimulates adenyl cyclase, resulting in accumulation of cyclic adenosine monophosphate at beta2—adrenergic receptors resulting in bronchodilation.

Therapeutic effects

Bronchodilation with decreased airflow obstruction.


Absorption: Umeclidinium—minimal oral absorption; remainder of absorption occurs in lungs; vilanterol—minimal oral absorption; remainder of absorption occurs in lungs. Total amount of systemic absorption of both drugs is small.
Distribution: Unknown.
Metabolism and Excretion: Umeclidinium—primarily metabolized by CYP2D6, metabolites do not contribute to bronchodilation; vilanterol—primarily metabolized by CYP3A4, metabolites do not contribute to bronchodilation.
Half-life: Umeclidinium—11 hr; vilanterol—11 hr.

Time/action profile (bronchodilation)

umeclidinium —Inhaln unknown2–4 hr24 hr
vilanterol—Inhalnunknown2–4 hr24 hr


Contraindicated in: Severe/acute symptoms of airflow obstruction; Severe hypersensitivity to milk proteins or other ingredients;Concurrent use with other anticholinergics; Lactation: Discontinue drug or discontinue breastfeeding.
Use Cautiously in: Concurrent use with strong inhibitors of CYP3A4 (↑ risk of cardiovascular adverse reactions); Narrow-angle glaucoma (may cause acute angle closure);History of seizures;Thyrotoxicosis;History of cardiovascular disorders (coronary insufficiency, arrhythmias, hypertension;Urinary retention, prostatic hyperplasia, bladder-neck obstruction);Severe hepatic impairment; Geriatric: Elderly patients may be more sensitive to drug effects; Obstetric: Use during pregnancy only if potential benefit justifies potential fetal risk; Pediatric: Safe and effective use in children has not been established.
Exercise Extreme Caution in: Concurrent use with MAOIs or tricyclic antidepressants (↑ risk of adverse cardiovascular reactions from vilanterol).

Adverse Reactions/Side Effects


Central nervous system

  • headache
  • vertigo


  • cough
  • pharyngitis
  • sinusitis


  • chest pain
  • pleuritic pain


  • abdominal pain
  • nausea


  • arthralgia
  • back pain
  • extremity pain
  • muscle spasms
  • neck pain


  • hypersensitivity reactions
  • tooth pain

Ear, Eye, Nose, Throat

  • acute narrow-angle glaucoma


  • paradoxical bronchospasm (life-threatening)


  • chest pain


  • urinary retention


  • arrhythmias
  • ECG changes
  • hypertension


  • hyperglycemia

Fluid and Electrolyte

  • hypokalemia


  • asthma-related death (life-threatening)


Drug-Drug interaction

↑ risk of adverse anticholinergic adverse reactions when used concurrently with other anticholinergics (avoid concurrent use).Concurrent use with MAOIs or tricyclic antidepressants ↑ risk of adverse cardiovascular reactions from vilanterol (use with extreme caution). Concurrent use with strong CYP3A4 inhibitors including ketoconazole may ↑ risk of adverse cardiovascular effects (use cautiously). Concurrent use with non-potassium sparing diuretics may ↑ risk of hypokalemia and adverse cardiovascular reactions (use cautiously). Concurrent use withbeta blockers may ↓ effectiveness and cause severe bronchospasm (use cautiously). Should not be used concurrently with any other long-acting beta2-adrenergic blockers.


Inhalation (Adults) One inhalation (umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily.


Inhalation powder (contains lactose): umeclidinium 62.5 mcg/vilanterol 25 mcg in a two-strip blister per dose

Nursing implications

Nursing assessment

  • Assess lung sounds, pulse, and BP before administration and periodically during therapy.
  • Observe for paradoxical bronchospasm (wheezing, dyspnea, tightness in chest) and hypersensitivity reaction (rash; urticaria; swelling of the face, lips, or eyelids). If condition occurs, discontinue medication, notify health care professional immediately, and treat symptomatically.
  • Assess for signs and symptoms of acute narrow-angle glaucoma (eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Notify health care professional immediately if symptoms occur.
  • Lab Test Considerations: May cause hypokelamia and hyperglycemia.

Potential Nursing Diagnoses

Ineffective airway clearance (Indications)
Activity intolerance


  • See for administration of inhalation medications. Once removed from foil tray, discard inhaler when counter reads 0 or 6 wk have passed, whichever comes first. Inhaler is not reusable; do not attempt to take inhaler apart.
    • When umeclidinium/vilanterol is administered concurrently with other inhalation medications, administer short-acting adrenergic bronchodilators first, followed by umeclidinium/vilanterol, then corticosteroids. Wait 5 min between medications.

Patient/Family Teaching

  • Instruct patient in proper use of inhaler and to take medication at the same time each day as directed. Do not stop without consulting health care professional. Take missed doses as soon as remembered during day. Do not double doses or take 2 doses in 1 day. Advise patient to read Medication Guide and Instructions for Use before starting therapy and with each Rx refill in case of changes.
  • Instruct patient using never to exhale into inhaler device and always to hold device in a level horizontal position. Mouthpiece should be kept dry; never wash.
  • Caution patient not to use umeclidinium/vilanterol to treat asthma or acute symptoms. A rapid-acting inhaled beta-adrenergic bronchodilator should be used for relief of acute attacks.
  • Advise patient to notify health care professional immediately if difficulty in breathing persists after use of umeclidinium/vilanterol, if condition worsens, or if more inhalations of rapid-acting bronchodilator than usual are needed to relieve an acute attack.
  • Advise patient to notify health care professional if signs and symptoms of urinary retention (difficulty urinating, painful urination, urinating frequently, urination in a weak stream or drips) or palpitations, chest pain, rapid heart rate, tremor, or nervousness occur
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
  • Emphasize the importance of regular follow-up exams to determine progress during therapy.

Evaluation/Desired Outcomes

  • Decreased dyspnea
    • Improved breath sounds in patients with COPD.
References in periodicals archive ?
Tell your doctor if you take anticholinergics (including umeclidinium, tiotropium, ipratropium, aclidinium, glycopyrrolate), because taking them together with Utibron or Seebri can increase side effects.
Once-daily combination treatment with umeclidinium and vilanterol was more effective than twice-daily combination treatment with fluticasone and salmeterol in patients with moderate to severe chronic obstructive pulmonary disease in two 12-week double-blind, parallel-group double-dummy studies.
relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium and vilanterol (the "Closed Triple").
Anoro is a once-daily combination treatment comprised of two bronchodilators, umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single inhaler, the Ellipta.
Some of the drugs which are major contributors to this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.
5mcg), or umeclidinium 125mcg (an unlicensed dose) in addition to RelvarA/BreoA ElliptaA (fluticasone furoate/vilanterol, FF/VI ), an inhaled corticosteroid / long-acting beta2-agonist combination, achieved an additional improvement in lung function (FEV1) compared to patients receiving FF/VI plus placebo.
GlaxoSmithKline plc today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), administered using the Ellipta dry powder inhaler.
Anoro is a once-daily combination treatment comprising two bronchodilators, umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single inhaler, the Ellipta.
relating to certain drug programs, including the combination of umeclidinium, vilanterol and fluticasone furoate (or the "Closed Triple").
Umeclidinium is GSK s first once-daily anticholinergic, a type of bronchodilator also known as a long-acting muscarinic antagonist (LAMA), and is contained in the ElliptaA inhaler.
5mcg of umeclidinium dry inhalation powder, administered once-daily using the Ellipta inhaler.
The EMA assessment of umeclidinium included a review of seven phase III clinical trials which included over 2,500 COPD patients treated with umeclidinium or placebo.